Anthos Therapeutics

We’re very pleased to announce Laurel Ostrom as Chief Human Resources Officer at #AnthosTherapeutics! Laurel brings a proven track record in scaling operations, driving HR strategy, and building high-performing teams in dynamic environments. Her leadership will be crucial in shaping the talent and culture needed to support Anthos’ continued growth, as we take the company to new heights. Welcome, Laurel. To learn more about Anthos Therapeutics, please visit our website: https://bit.ly/4aR1QMf. 

We’re excited to welcome Mia Kelley as General Counsel at #AnthosTherapeutics! Mia brings extensive experience in capital markets, business development and corporate governance, having supported major equity offerings, strategic collaborations and corporate growth initiatives. Mia’s leadership will help position Anthos for long-term success as we prepare for our next phase of growth. Welcome aboard, Mia! To learn more about Anthos Therapeutics, click here: https://bit.ly/4aR1QMf.

#Atrialfibrillation (#afib) affects more than 6 million Americans and increases the risk of #stroke by up to five times, according to the American Heart Association. While progress has been made, gaps in care remain. As September and #AfibAwarenessMonth come to a close, #AnthosTherapeutics proudly stands alongside advocacy groups such as StopAfib.org and the National Blood Clot Alliance for their daily efforts to raise awareness, educate, and advocate for patients. Research into therapies like #FactorXI inhibitors offers new hope for those living with atrial fibrillation. Learn more about Anthos Therapeutics and our clinical development program: 👉 https://bit.ly/4aR1QMf. #afibawareness #strokeawareness #thrombosis #hemostasis #innovation

#ICYMI at #ESC2024, be sure to check out this interview between Dr. C. Michael Gibson, M.S., M.D. and Dr. Siddharth Patel from the TIMI Study Group. Here, they discuss a new analysis from the landmark AZALEA-TIMI 71 #atrialfibrillation study, which focused on the use of a long-acting anticoagulant during a procedure. For Dr. Patel’s full ESC late-breaker presentation, click here: https://bit.ly/3HLiujf. #AFibAwarenessMonth #afibawareness #stroke #strokeawareness #thrombosis #hemostasis #innovation

DYK: 40-60% of patients diagnosed with #atrialfibrillation are either not on an #anticoagulant or are taking a less-than-optimal dose. This underuse has been described as one of the greatest public health issues facing #cardiovascular patients today. Thanks to the fantastic work of #afib patient advocacy leader StopAfib.org, awareness is growing and support is expanding as they continue to rally for positive change in patient care. At #AnthosTherapeutics, our innovative clinical development program, comprised of the now-completed landmark AZALEA-TIMI 71 and ongoing LILAC-TIMI 76 studies, is focused on closing the gap in #stroke protection for patients with atrial fibrillation through the promise of #FactorXI inhibition. #afibawareness #strokeawareness #thrombosis #hemostasis #innovation

Thank you, North American Thrombosis Forum (NATF), for the great work you do to advance #thrombosis research and education. CC: Christian Ruff John Fanikos

Periprocedural data presented at the #ESCCongress by Dr. Siddharth Patel from the TIMI Study Group builds on the growing body of evidence supporting the potential safety of the novel, investigational, once-monthly administered, highly selective, fully human monoclonal antibody #abelacimab.   This new analysis of the landmark AZALEA-TIMI 71 study explored one of the most tenuous times for people taking #anticoagulants – when they need to undergo a procedure.   #FactorXI inhibitors, like abelacimab, could represent a pivotal paradigm shift in the future of #anticoagulation therapy and patient care.    Read the press release in full: https://bit.ly/3z0MiaO.   #ESCCongress #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis

“For patients who are taking current standard-of-care #anticoagulants to mitigate their risk of #stroke, it can be frightening to have to stop taking treatment – even temporarily – to undergo any procedure.” - Mellanie True Hills, CSP, Founder and CEO of StopAfib.org.   A new analysis from the AZALEA-TIMI 71 study just presented at the European Society of Cardiology (ESC) Congress by Dr. Siddharth Patel from the TIMI Study Group, demonstrated that #abelacimab was associated with very low levels of periprocedural bleeding in patients with #atrialfibrillation.   Read the press release in full: https://bit.ly/3z0MiaO.   #ESCCongress #FactorXI #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis

#NEWS: #AnthosTherapeutics announced today, at a late-breaking session of the European Society of Cardiology (ESC) Congress, a new analysis from the landmark AZALEA-TIMI 71, demonstrating that #abelacimab was associated with very low levels of periprocedural bleeding in patients with #atrialfibrillation. The new analysis presented by Dr. Siddharth Patel from the TIMI Study Group found that approximately 1% of patients taking abelacimab experienced a major or clinically relevant non-major (CRNM) bleed while undergoing a procedure. This data further substantiates the growing body of evidence supporting the safety profile of abelacimab, a novel once-monthly administered, highly selective, fully human monoclonal antibody currently being studied in Phase 3 trials. Read the press release in full: https://bit.ly/3z0MiaO.   #ESCCongress #FactorXI #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis

Dr. Siddharth Patel from the TIMI Study Group will present periprocedural data from the landmark AZALEA-TIMI 71 #atrialfiibrillation study as a late-breaker at the European Society of Cardiology (ESC) Congress 2024. Save the date! Check out the #ESCCongress late-breaker program here 👉: https://bit.ly/3WUUDVe. #afib #afibawareness #strokeawareness #FactorXI #FactorXIa #thrombosis #hemostasis #anticoagulant #anticoagulation #abelacimab #AnthosTherapeutics